Levetiracetam Sun

Levetiracetam, the active ingredient in Levetiracetam Sun, is an anticonvulsant presented as an injection solution for intravenous use. It is employed to manage partial, generalized tonic‑clonic and myoclonic seizures in adult and pediatric patients, especially when rapid or controlled seizure control is required.

GNH USA supplies Levetiracetam Sun as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, clinics and procurement teams worldwide. The company adheres to EU GMP guidelines and offers temperature‑controlled logistics to ensure product integrity from manufacturing to end‑user.

Levetiracetam is an antiepileptic agent used to control seizure activity in various epilepsy syndromes.

- Partial seizures: reduces frequency and severity of focal seizures. - Generalized tonic‑clonic seizures: helps achieve seizure freedom in convulsive episodes. - Myoclonic seizures: decreases occurrence of sudden muscle jerks.

Levetiracetam may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Dizziness - Somnolence - Fatigue - Headache - Irritability - Nausea

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Blood dyscrasias (e.g., neutropenia, thrombocytopenia) - Suicidal thoughts or worsening depression - Respiratory depression in susceptible individuals - Severe skin reactions

When using Levetiracetam Sun, clinicians should consider several safety measures. - Renal impairment: monitor renal function and adjust dosing as needed. - Hepatic impairment: use with caution and observe liver enzymes. - Pregnancy: Category B; discuss potential risks and benefits with the patient. - Concomitant CNS depressants: monitor for additive sedation. - Discontinue gradually: avoid abrupt cessation to reduce seizure recurrence. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam has a relatively low potential for drug‑drug interactions, but certain combinations require attention.

Major Interactions (Avoid): - None identified: no major pharmacokinetic interactions requiring avoidance have been reported.

Moderate Interactions (Monitor Closely): - Phenobarbital: may modestly reduce levetiracetam plasma concentrations. - Carbamazepine: may slightly decrease levetiracetam levels. - Other antiepileptics: monitor for additive central nervous system effects.